| Liu, Yu C |
NCT06216340: Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes |
|
|
| Not yet recruiting | 4 | 300 | NA | Henagliflozin, diet-exercise therapy, Placebo | The First People's Hospital of Changzhou, The Second Hospital of Nanjing Medical University, The First Affiliated Hospital of Soochow University, Second Affiliated Hospital of Soochow University, Wuxi People's Hospital, Northern Jiangsu People's Hospital, The Affiliated Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Affiliated Hospital of Jiangsu University, The fourth affiliated hospital of nantong university | Obese, Weight Loss, Pre-diabetes | 10/26 | 10/26 | | |
| Completed | 3 | 533 | RoW | Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage | Chipscreen Biosciences, Ltd. | Type 2 Diabetes | 02/23 | 02/23 | | |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
NCT05102149: Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 3 | 672 | RoW | PB-201, Vildagliptin, PB-201 matched placebo, Vildagliptin matched placebo | PegBio Co., Ltd. | Type 2 Diabetes Mellitus (T2DM) | 11/23 | 04/25 | | |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
| Not yet recruiting | 3 | 358 | RoW | TQB2450+Anlotinib, TQB2450 placebo + Anlotinib placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Small Cell Lung Cancer Limited Stage | 09/26 | 09/26 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
| Recruiting | N/A | 150 | RoW | 99mTc-HFAPI | Peking Union Medical College Hospital | Pulmonary Fibrosis | 07/23 | 07/24 | | |
| Completed | N/A | 2071 | RoW | pancreatic extracorporeal shock wave lithotripsy | Changhai Hospital | Pancreatic Duct Stone | 04/24 | 05/24 | | |
NCT06725212: Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia |
|
|
| Recruiting | N/A | 126 | RoW | Water Vapor Thermal Ablation, Water Vapor Ablation, Cystoscopy | Medtecx Co Ltd. | Benign Prostatic Hyperplasia | 06/25 | 06/26 | | |
NCT06581653: Medication Adherence to Phone-supervised Pancreatic Enzyme Replacement Therapy |
|
|
| Recruiting | N/A | 206 | RoW | Phone-based PERT education intervention | Changhai Hospital | Chronic Pancreatitis, Pancreatic Exocrine Insufficiency | 03/25 | 12/25 | | |
| Sanborn, Rachel E |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT05275673: A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer |
|
|
| Terminated | 2 | 7 | US | sapanisertib, CB-228 | Calithera Biosciences, Inc | Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer, Squamous Non-Small Cell Neoplasm of Lung, NFE2L2 Gene Mutation | 03/23 | 03/23 | | |
RAMOSE, NCT03909334: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 2 | 160 | US | Osimertinib, Tagrisso, Ramucirumab, Cyramza | Xiuning Le, M.D. Anderson Cancer Center, Eli Lilly and Company | Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer | 09/25 | 10/25 | | |
NCT04364048: Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer |
|
|
| Terminated | 2 | 10 | US | Induction Durvalumab, IMFINZI, Chemotherapy, cisplatin, carboplatin, etoposide, pemetrexed, taxane, Radiation, Consolidation durvalumab | Rachel Sanborn, AstraZeneca, Providence Cancer Center, Earle A. Chiles Research Institute | Lung Cancer, Non-small Cell Carcinoma | 06/23 | 02/24 | | |
| Active, not recruiting | 2 | 68 | US, RoW | Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta® | Effector Therapeutics, Medpace, Inc., ICON plc | Non-small Cell Lung Cancer | 10/24 | 12/24 | | |
|
CA209-8H3, NCT03650894: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients |
|
|
| Active, not recruiting | 2 | 30 | US | Nivolumab, Opdivo, Ipilimumab, Yervoy, Bicalutamide, Casodex | Providence Health & Services, Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center | Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor | 01/25 | 01/26 | | |
BTCRC-LUN18-153, NCT04317534: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm |
|
|
| Recruiting | 2 | 244 | US | Pembrolizumab | Greg Durm, MD, Merck Sharp & Dohme LLC | NSCLC, Stage I | 04/26 | 04/29 | | |
| Recruiting | 2 | 160 | Europe, Canada, US, RoW | disitamab vedotin, RC48, RC48-ADC | Seagen Inc. | Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms | 05/26 | 05/28 | | |
NCT02422381: MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 1/2 | 16 | US | MK-3475, Anti-PD-1, Pembrolizumab, Gemcitabine, Gemzar | Providence Health & Services, Merck Sharp & Dohme LLC, Providence Cancer Center, Earle A. Chiles Research Institute | Carcinoma, Non-Small-Cell Lung | 01/19 | 08/24 | | |
NCT03847519: Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer |
|
|
| Completed | 1/2 | 24 | US | ADXS-503, Lm immunotherapy, A503, Pembrolizumab, Keytruda, pembro | Advaxis, Inc. | Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma | 02/22 | 02/22 | | |
| Recruiting | 1/2 | 232 | US | MK-6070, HPN328, Atezolizumab, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Daiichi Sankyo | Small-Cell Lung Cancer, Neuroendocrine Carcinoma | 02/26 | 02/26 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Active, not recruiting | 1/2 | 284 | Europe, Japan, US, RoW | CLN-081, TAS6417; zipalertinib | Cullinan Therapeutics Inc. | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | 12/24 | 12/24 | | |
|
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
| Active, not recruiting | 1/2 | 49 | Europe, Japan, US, RoW | TAK-981, Pembrolizumab | Takeda, Takeda Development Center Americas, Inc. | Advanced or Metastatic Solid Tumors | 11/25 | 11/25 | | |
Acclaim-3, NCT05703971: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients |
|
|
| Recruiting | 1/2 | 62 | US | quaratusugene ozeplasmid, REQORSA, atezolizumab, TECENTRIQ | Genprex, Inc. | Small Cell Lung Cancer Extensive Stage | 02/26 | 08/27 | | |
KEYNOTE A99, NCT04198766: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) |
|
|
| Recruiting | 1/2 | 333 | US | INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, KEYTRUDA, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Alimta®, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2 | Inhibrx Biosciences, Inc, Merck Sharp & Dohme LLC | Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma | 02/26 | 05/26 | | |
| Active, not recruiting | 1/2 | 344 | Europe, Canada, Japan, US, RoW | JDQ443, TNO155, tislelizumab | Novartis Pharmaceuticals | KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms | 04/26 | 04/26 | | |
NCT04250597: Study of GNX102 in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1 | 46 | US, RoW | GNX102 | GlycoNex, Inc. | Solid Tumor, Metastatic Cancer, Advanced Cancer, Unresectable Solid Neoplasm | 07/23 | 07/23 | | |
NCT05108623: A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors |
|
|
| Completed | 1 | 34 | US | agenT-797, Approved ICIs | MiNK Therapeutics | Tumor, Solid | 01/24 | 01/24 | | |
NCT05142592: Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 196 | US, RoW | IPG7236 | Nanjing Immunophage Biotech Co., Ltd | Safety Issues, Tolerability, Pharmacokinetics | 09/25 | 12/25 | | |
NCT05375084: SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation |
|
|
| Terminated | 1 | 21 | US | BBP-398 with nivolumab | Navire Pharma Inc., a BridgeBio company, Bristol-Myers Squibb | Non Small Cell Lung Cancer, Solid Tumor | 04/24 | 07/24 | | |
| Recruiting | 1 | 824 | Europe, US, RoW | sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin | Seagen Inc. | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms | 11/26 | 02/28 | | |
| Recruiting | 1 | 550 | Europe, US | Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1 | Agenus Inc. | Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer | 12/26 | 12/26 | | |
NCT03809624: Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer |
|
|
| Terminated | 1 | 160 | US | INBRX-105 - PDL1x41BB antibody, Pembrolizumab, Keytruda | Inhibrx Biosciences, Inc | Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma | 10/24 | 10/24 | | |
| Recruiting | 1 | 275 | Europe, US | SGN-EGFRd2 | Seagen Inc. | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma | 07/27 | 09/28 | | |
NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies |
|
|
| Recruiting | 1 | 270 | US | PRTH-101, Pembrolizumab | Incendia Therapeutics | Advanced or Metastatic Solid Tumors | 09/27 | 09/27 | | |
| Li, Ning |
NCT04351867: A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer |
|
|
| Not yet recruiting | 3 | 196 | RoW | docetaxel plus oxaliplatin and capecitabine, Three medicine combined, oxaliplatin plus capecitabine, Two medicine combined | LiNing | Stomach Neoplasms | 06/24 | 06/24 | | |
NCT06658353: Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors |
|
|
| Not yet recruiting | 3 | 54 | RoW | VC004 Capsules | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor | 12/26 | 12/26 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
|
NCT03950271: SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 25 | RoW | SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine | Henan Cancer Hospital | Gastric Cancer | 01/24 | 12/26 | | |
NeoTOP, NCT06618014: Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC |
|
|
| Completed | 2 | 51 | RoW | Toripalimab, Docetaxel, Carboplatin | Sun Yat-sen University | Breast Cancer, Triple Negative Breast Cancer | 10/24 | 01/25 | | |
NCT04341857: PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 25 | RoW | PD-1 Monoclonal Antibody(Sintilimab) | Henan Cancer Hospital | Gastric and Esophagogastric Junction Adenocarcinoma | 05/22 | 07/22 | | |
NCT04423185: PLATFORM Study of Precision Medicine for Rare Tumors |
|
|
| Not yet recruiting | 2 | 770 | NA | Almonertinib 110 MG, HS-10296, AMEILE, Dacomitinib 45 MG, Vizimpro, Alectinib 150 MG, Alecensa, Crizotinib 250 MG, Xalkori, Pyrotinib 160/80 MG, SHR-1258, Imatinib 400 MG, Gleevec, Niraparib 200/300 MG, Niraparix, Palbociclib 125mg, Ibrance, Vemurafenib 240 MG, Zelboraf, Sintilimab 100MG, Tyvyt, Atezolizumab 1680 MG, TECENTRIQ | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Rare Tumor | 07/22 | 07/23 | | |
NCT04062058: A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 82 | RoW | SIB-IMRT, S-1, SOX, Surgery | Jing Jin, M.D., Beijing Hope Run | Gastric Cancer, Neoadjuvant Therapy | 09/22 | 09/23 | | |
NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 115 | RoW | VC004 | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 01/24 | 06/24 | | |
NCT06322095: A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 2 | 72 | RoW | PD-1, MET inhibitor, ALK inhibitor, BRAF Inhibito, EGFR Monoclonal antibody, GH21, MEK Inhibitor | Suzhou Genhouse Bio Co., Ltd. | Patients With Advanced Solid Tumor, Advanced Solid Tumor With Oncogenic Driver Mutations | 09/25 | 12/25 | | |
NCT06490068: Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy |
|
|
| Recruiting | 2 | 10 | RoW | LTC004+Toripalimab, LTC004 combine with Toripalimab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Solid Tumor | 03/26 | 03/26 | | |
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC |
|
|
| Recruiting | 2 | 60 | RoW | HLX07+HLX10+ Cisplatin+5-FU, HLX07 | Shanghai Henlius Biotech | ESCC or Esophageal Adenosquamous Carcinoma | 06/24 | 08/25 | | |
| Not yet recruiting | 2 | 15 | RoW | ES014, ES014 for Injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Elpiscience (Suzhou) Biopharma, Ltd. | Advanced Solid Tumor | 06/26 | 09/26 | | |
| Not yet recruiting | 2 | 42 | RoW | Neratinib tablets, Epilepsy | Convalife (Shanghai) Co., Ltd. | NSCLC | 12/24 | 12/25 | | |
| Not yet recruiting | 2 | 90 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gynecological Tumors | 05/26 | 11/26 | | |
NCT04348643: Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer |
|
|
| Recruiting | 1/2 | 40 | RoW | CEA CAR-T cells | Chongqing Precision Biotech Co., Ltd | Solid Tumor, Lung Cancer, Colorectal Cancer, Liver Cancer, Pancreatic Cancer, Gastric Cancer, Breast Cancer | 12/23 | 04/24 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
| Recruiting | 1/2 | 134 | US, RoW | PRO1160 | ProfoundBio US Co. | Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma | 11/26 | 03/27 | | |
NCT06612632: Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials |
|
|
| Recruiting | 1/2 | 100 | RoW | research drug in combination with Toripalimab, Toripalimab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Cancer | 06/26 | 06/28 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT05538195: Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1/2 | 60 | RoW | CEA-targeted CAR-T cells | Chongqing Precision Biotech Co., Ltd | Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreatic Cancer | 12/24 | 06/25 | | |
| Recruiting | 1/2 | 404 | US, RoW | Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab | Genmab | Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer | 04/26 | 10/26 | | |
NCT06088004: Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 218 | RoW | ABO2011 Injection, ABO2011, ABOD2011, Toripalimab | Suzhou Abogen Biosciences Co., Ltd., Abogen Biosciences (Shanghai) Co., Ltd | Solid Tumor, Adult | 12/26 | 12/27 | | |
NCT04615312: A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors |
|
|
| Recruiting | 1 | 50 | RoW | a CDK4 / 6 inhibitor and a MEK inhibitor | Henan Cancer Hospital | Digestive System Tumors | 08/21 | 08/22 | | |
NCT04326296: The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer |
|
|
| Not yet recruiting | 1 | 33 | RoW | PD-L1 Monoclonal Antibody Combined With Lenalidomide | LiNing | Colorectal Neoplasms | 09/22 | 03/23 | | |
NCT05881525: NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | TC-N201 cells, IL-2, Fludarabine, Cyclophosphamide, Nab-paclitaxel | TCRCure Biopharma Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Solid Tumors | 10/24 | 03/25 | | |
NCT06205082: A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor |
|
|
| Enrolling by invitation | 1 | 81 | RoW | LIT-00814 | LittDD Medicines Ltd | Advanced Solid Tumor | 10/25 | 06/26 | | |
KSX01-R08-102, NCT06150365: Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 12 | RoW | KSX01-TCRT cell therapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Refractory Solid Tumors, Relapsed Solid Tumors | 12/26 | 12/28 | | |
NCT05152212: Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy |
|
|
| Completed | 1 | 33 | RoW | LVGN7409 | Lyvgen Biopharma Holdings Limited | Cancer | 12/23 | 12/23 | | |
NCT06342336: HS-IT101 Injection in the Treatment of Advanced Solid Tumors |
|
|
| Recruiting | 1 | 44 | RoW | HS-IT101 Injection, HS-IT101 | Qingdao Sino-Cell Biomedicine Co., Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences, The First Hospital of Jilin University, West China Hospital | Solid Tumor | 03/26 | 03/28 | | |
| Recruiting | 1 | 60 | RoW | BT02 monoclonal antibody injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Solid Tumor | 12/24 | 12/24 | | |
NCT05183243: GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results |
|
|
| Recruiting | 1 | 68 | RoW | GH21 Capsule | Suzhou Genhouse Bio Co., Ltd. | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Head and Neck Neoplasm | 12/24 | 02/25 | | |
NCT06328673: A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 160 | US, RoW | DM919, Pembrolizumab, Keytruda | D2M Biotherapeutics Inc. | Advanced Solid Tumor | 12/25 | 03/26 | | |
NCT06346041: Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 19 | RoW | Oncolytic Virus injection(IDOV-SAFETM) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Neoplasms | 12/25 | 04/26 | | |
| Recruiting | 1 | 112 | RoW | TQB3006 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Neoplasm | 03/25 | 08/26 | | |
| Terminated | 1 | 3 | RoW | TQB2928 injection, Penpulimab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Neoplasm | 07/24 | 07/24 | | |
NCT06410131: Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16 |
|
|
| Not yet recruiting | 1 | 68 | RoW | FTL008.16 | Sound Biopharmaceuticals Ltd. | Solid Tumors | 01/26 | 05/27 | | |
NCT05886868: Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 66 | RoW | BL0020 | Shanghai Best-Link Bioscience, LLC | Advanced Solid Tumor | 07/24 | 02/25 | | |
NCT06736275: A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients with Advanced Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | SXRN | Jiangsu Nutai Biologics Co., Ltd, Chinese Academy of Medical Sciences | Advanced Cancer, Cachexia | 09/25 | 12/25 | | |
| Not yet recruiting | 1 | 30 | NA | JYB1907, TGF-β inhibitor | Jemincare | Solid Tumor | 09/24 | 10/24 | | |
NCT06001684: Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | IBR854 Cell Injection | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Solid Tumors | 09/24 | 12/24 | | |
NCT06610227: A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients with Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 18 | NA | SapRNA™-MICA/B Tumor Vaccine | NING LI | Advanced Solid Tumors | 10/25 | 10/26 | | |
| Recruiting | 1 | 122 | RoW | SG1827 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Solid Tumors | 12/24 | 03/25 | | |
NCT06740019: A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion |
|
|
| Not yet recruiting | 1 | 30 | RoW | JMKX000197, Tube thoracostomy drainage | Jemincare | Malignant Pleural Effusions (Mpe) | 12/25 | 11/26 | | |
| Recruiting | 1 | 100 | RoW | HQP1351 | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult | 12/24 | 12/26 | | |
NCT06742593: Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1 | 12 | RoW | MT027 cells suspension | Suzhou Maximum Bio-tech Co., Ltd. | Brain (Nervous System) Cancers, Brain and Central Nervous System Tumors, Brain Tumors | 12/25 | 12/26 | | |
NCT06717750: A Study of CSCJC3456 in Patients with Advanced Malignant Tumors |
|
|
| Not yet recruiting | 1 | 102 | RoW | CSCJC3456 tablet | Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. | Advanced Malignant Solid Tumors | 06/27 | 06/28 | | |
NCT06796699: A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects with MTAP-Deleted Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 90 | RoW | GH56 Capsule | Suzhou Genhouse Bio Co., Ltd. | Subjects with MTAP-Deleted Advanced Solid Tumors | 12/27 | 02/28 | | |
NCT05392699: ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy |
|
|
| Recruiting | 1 | 60 | RoW | human single chain IL-12 mRNA-single dose, human single chain IL-12 mRNA-multiple dose | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Patients With Advanced Solid Tumors | 03/25 | 01/27 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
| Recruiting | 1 | 71 | RoW | TQB2103 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Malignant Neoplasm | 05/25 | 05/25 | | |
NCT06050980: Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 1 | 220 | RoW | HSK40118 | Haisco Pharmaceutical Group Co., Ltd. | NSCLC | 08/25 | 06/27 | | |
NCT05946226: A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors |
|
|
| Recruiting | 1 | 18 | RoW | IMC002 injection, Autologous Claudin 18.2 specific CAR-T cell injection | Suzhou Immunofoco Biotechnology Co., Ltd | Advanced Digestive System Tumor | 12/25 | 12/25 | | |
NCT06314542: Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world Data |
|
|
| Recruiting | N/A | 50000 | RoW | relaxing eligibility criteria | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, AstraZeneca | Lung Cancer | 12/25 | 06/26 | | |
NCT04891900: TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Active, not recruiting | N/A | 25 | RoW | TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine, PD-L1 inhibitor/Anlotinib | Henan Cancer Hospital | Gastric Cancer, Adenocarcinoma of Esophagogastric Junction | 12/24 | 12/24 | | |
NCT05458778: Detection of Urinary Human Chorionic Gonadotropin (hCG) |
|
|
| Recruiting | N/A | 200 | US | Daily test with urine by the product | Quanovate Tech Inc. | Pregnancy Detection | 10/23 | 10/23 | | |
NCT05609058: The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target |
|
|
| Recruiting | N/A | 300 | RoW | dedicated treatment board with no degree | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Breast Cancer | 11/23 | 11/23 | | |
